Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leathanach 1 ó 57 torthaí
Treatment of emesis with morpholine tachykinin receptor antagonists
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
SUMMARY OF THE INVENTION
This invention is concerned with novel compounds represented by structural formula I: ##STR2## wherein R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, B, p, Y and Z are hereinafter defined.
The invention is also concerned with pharmaceutical
Benzoimidazole derivatives and pharmaceutical composition comprising the same
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
TECHNICAL FIELD
The present invention relates, in general, to novel benzoimidazole derivatives and, more particularly, to novel benzoimidazole derivatives functioning as antagonists to a vanilloid receptor (capsaicin receptor; Transient Receptor Potential Channel, Vanilloid subfamily member 1;
Opioid compounds and methods for using same
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
Opioid compounds
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
Opioid compounds and methods for making therefor
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to diarylmethyl piperazine compounds having utility in medical therapy especially as receptor-binding species, e.g., as conjugates in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter
Piperidine derivatives as substance P antagonists
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
This application is a 371 of PCT/JP96/00796 filed Mar. 27, 1996.
TECHNICAL FIELD
The present invention relates to new piperidine derivatives having an antagonism on Substance P, being a peptide neurotransmitter, and pharmaceutically acceptable acid addition salts thereof. The piperidine derivatives
.DELTA.9 Tetrahydrocannabinol (.DELTA.9 THC) solution metered dose inhaler
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
DESCRIPTION
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention is generally related to the therapeutic use of .DELTA..sup.9 Tetrahydrocannabinol (.DELTA..sup.9 THC). In particular, the invention provides a metered dose inhaler (MDI) for the aerosol administration of .DELTA..sup.9
.DELTA.9 tetrahydrocannabinol (.DELTA.9 THC) solution metered dose inhalers and methods of use
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention is generally related to the therapeutic use of .DELTA..sup.9 Tetrahydrocannabinol (.DELTA..sup.9 THC). In particular, the invention provides a metered dose inhaler (MDI) for the aerosol administration of .DELTA..sup.9 THC to
Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists
Modulation of substance P by compounds containing calcium sulfate and methods relating thereto
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
TECHNICAL FIELD
The present invention relates generally to a method of modulating substance P by compounds containing calcium sulfate, particularly syngenite, gorgeyite and gypsum, and more specifically, to the synthesis of such compounds as well as their use to treat a variety of conditions
Protein free formula
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The present invention relates to the stimulation of health in infants receiving an amino acid based formula.
BACKGROUND OF THE INVENTION
In a preferred situation, infants are breastfed by the mother. However, often in infants, after an initial period of being breast fed,
Benzyloxyquinuclidines as substance P antagonists
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
This application is the U.S. national phase of PCT Patent Application PCT/JP94/01092, which was filed in the Japanese Receiving Office on Jul. 5, 1994.
This invention relates to novel and useful benzyloxyquinuclidines of interest to those in the field of medical chemistry
Bi-pyridinyl derivatives as NK-1 antagonists
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
PRIORITY TO RELATED APPLICATIONS
This application claims the benefit of European Application No. 05101324.1, filed Feb. 22, 2005, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Substance P is a naturally occurring undecapeptide belonging to the tachykinin
Methods of screening for agonists and antagonists of the interaction between the human KIAA0001 receptor and ligands thereof
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also
Aroyl-piperidine derivatives and method of treating disorders induced by substance P
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
DETAILED DESCRIPTION OF THE INVENTION
The invention relates to novel N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(quinoloylamino)-piperidin- es of the formula
##STR00002## wherein Y is .dbd.N-- or .dbd.N(O)--, R is OH when Y is .dbd.N-- and R is H when Y is .dbd.N(O)-- and the ring A is
An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht
- Oibreacha i 55 teanga
- Leigheasanna luibhe le tacaíocht ón eolaíocht
- Aitheantas luibheanna de réir íomhá
- Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
- Léigh foilseacháin eolaíochta a bhaineann le do chuardach
- Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
- Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní
Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe
